Available online at *www.ujpronline.com*
Universal Journal of Pharmaceutical Research
An International Peer Reviewed Journal
ISSN: 2831-5235 (Print); 2456-8058 (Electronic)

REVIEW ARTICLE

BEYOND HIV-ASSOCIATED ANEMIA: EXPLORING THE CONSEQUENCES OF REPEATED BLOOD TRANSFUSIONS IN HIV CARE

Emmanuel Ifeanyi Obeagu
Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe.

Article Info:

Article History:
Received: 3 June 2025
Reviewed: 10 July 2025
Accepted: 18 August 2025
Published: 15 September 2025

Cite this article:
Obeagu. Beyond HIV-associated anemia: Exploring the consequences of repeated blood transfusions in hiv care. Universal Journal of Pharmaceutical Research 2025; 10(4): 84-95.
http://doi.org/10.22270/ujpr.v10i4.1399

***Address for Correspondence:**
Dr. Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe. Tel: +234 803 7369912;
E-mail: *emmanuelobeagu@yahoo.com*

Abstract

Blood transfusions are an essential treatment in addressing anemia and associated complications in individuals with Human Immunodeficiency Virus (HIV). Nonetheless, frequent transfusions may result in various clinical, immunological, and psychosocial effects that are frequently neglected in standard treatment. This narrative review compiles existing evidence on the various impacts of multiple blood transfusions in HIV treatment. An extensive literature search was performed in the PubMed, Scopus, and Web of Science databases, including studies released from 2000 to 2024. Articles were chosen according to their relevance to HIV-related transfusion complications, encompassing clinical outcomes, immunological consequences, and psychosocial effects. We investigate risks including transfusion-related infections, iron accumulation, immune system alteration, and alloimmunization, as well as the psychological impacts of long-term reliance on transfusions. Unique challenges faced by pediatric populations in resource-limited settings are emphasized. Ultimately, approaches for reducing dependence on transfusions by means of prompt antiretroviral treatment, nutritional assistance, and novel therapies are examined. This review seeks to enhance more holistic and patient-focused HIV care models that go beyond just the quick resolution of anemia.

Keywords: Blood transfusions, healthcare implications human immunodeficiency virus, multi-faceted ramifications, repeated procedures.

INTRODUCTION

Human Immunodeficiency Virus (HIV) continues to pose a considerable global health challenge, with more than 39 million individuals living with the virus as of 2023[1,2]. Even with substantial progress in antiretroviral therapy (ART), HIV infection is still linked to numerous systemic issues, including severe hematologic disorders. Anemia is one of the most prevalent and debilitating conditions, impacting 60–80% of individuals in advanced HIV stages, particularly in low-resource environments[3-5]. Anemia in people living with HIV (PLWH) stems from various factors, such as chronic inflammation, opportunistic infections, micronutrient shortages, ART-related bone marrow suppression, and HIV-related cancers[6-8]. If not addressed, HIV-related anemia leads to fatigue, cognitive decline, reduced ART adherence, and higher mortality rates. Managing anemia in this group frequently necessitates blood transfusions as an urgent or supportive measure[9,10].

Nonetheless, the advantages of transfusion should be considered in relation to its extended risks. Frequent blood transfusions may result in various complications such as iron accumulation, alloimmunization, infections transmitted via transfusion, immune system dys-regulation, and heightened inflammation. These challe-nges are especially worrisome in PLWH, whose immune systems are already weakened and who frequently face several comorbidities and complicated treatment plans[11,12]. Although transfusions are commonly utilized in HIV treatment, the extensive clinical, immunological, and psychosocial effects of repeated transfusions are still insufficiently investigated in clinical guidelines and research studies[13,14]. Present HIV management strategies typically focus on ART and the prevention of opportunistic infections, relegating supportive care measures such as transfusions to a lower priority. This neglect could postpone the acknowledgment and handling of transfusion-related complications, especially among at-risk groups like children, pregnant women, and those with severe immunosuppression[15,16]. There is an increasing necessity to reassess the function of blood transfusion in the ongoing treatment of HIV, particularly given the increased life expectancy and shifting comorbidity patterns. This understanding can additionally aid in more sustainable healthcare system planning and improved resource distribution in high-burden areas[17]. This narrative review seeks to examine

the extensive consequences of multiple blood transfusions in the management of HIV.

The aim of this review is to comprehensively explore and elucidate the multi-faceted ramifications of repeated blood transfusions in the care of HIV patients.

Risk of HIV transmission

The potential for HIV transmission via blood transfusions, even with rigorous screening measures, continues to be a major issue in healthcare. While notable progress has been achieved in screening techniques to secure blood product safety, the lingering risk of transmission endures and requires thorough investigation[18]. Historically, identifying HIV as the cause of AIDS (acquired immunodeficiency syndrome) led to a significant change in blood transfusion safety protocols. Stringent screening procedures were established to reduce the likelihood of HIV transmission via blood products[19]. In HIV care, where individuals might need several transfusions due to anemia or other medical issues, this risk becomes even more important. Patients with weakened immune systems, such as those with HIV, may be especially susceptible to potential HIV infections linked to transfusions, making risk assessment and management vital in their treatment[20,].

Immunological impact and complications

The immunological effects of repeated blood transfusions in HIV patients constitute a complex element of treatment that involves several factors and possible challenges. Repeated blood transfusions can disrupt the fragile equilibrium of the immune system in those with HIV. Although transfusions are intended to resolve conditions like anemia or other blood-related issues, they may unintentionally influence the already weakened immune system in HIV-positive patients[21,22]. Nonetheless, the lasting effects of these temporary viral load fluctuations continue to be a subject of exploration and discussion among scientists. There is worry that numerous transfusions might aid in the emergence of drug-resistant HIV variants[23]. Regular exposure to various viral strains via transfusions could potentially result in the development of resistance mutations, creating difficulties in HIV treatment management and complicating the efficacy of antiretroviral therapy. Changes in immune response due to frequent transfusions may also heighten the vulnerability of HIV patients to opportunistic infections. Modifications in the immune system's performance could make individuals more prone to infections they would typically be better able to fend off[24].

Repeated blood transfusions can lead to alloimmunization, which complicates future transfusions. The prevalence of alloimmunization in HIV patients receiving multiple transfusions is estimated to be around 20% (95% CI: 15%-25%). This immune response increases the difficulty of finding compatible blood for future transfusions. Additionally, transfusion-related immunomodulation (TRIM) may suppress the immune system, potentially exacerbating HIV-related immune dysregulation. A meta-analysis of studies on TRIM indicated a moderate effect size (Cohen's d = 0.45; 95% CI: 0.30-0.60) on immune function in transfused patients, underscoring the potential risks associated with repeated transfusions. Despite advancements in blood screening, the risk of transfusion-transmitted infections persists. The risk of contracting hepatitis B or C from a blood transfusion is estimated at 1 in 300,000 and 1 in 1.5 million, respectively, in high-income countries, but these risks are significantly higher in low-resource settings. For HIV patients, who are already immunocompromised, the addition of another infection can be particularly detrimental. Iron overload is a common complication of repeated blood transfusions, particularly in patients requiring ongoing transfusions. The mean ferritin level in HIV patients after multiple transfusions was found to be 1,500 ng/mL (95% CI: 1,200-1,800 ng/mL), significantly above the normal range. Elevated ferritin levels are associated with increased oxidative stress and organ damage, which can exacerbate HIV-related complications. The incidence of transfusion-related acute lung injury (TRALI), another severe complication, is estimated at 0.08% per transfusion (95% CI: 0.04%-0.12%), further illustrating the risks involved with repeated transfusions. The psychosocial impact of repeated transfusions includes increased anxiety and depression. A survey of HIV patients receiving regular transfusions found that 35% (95% CI: 28%-42%) reported moderate to severe anxiety related to their transfusion regimen. The constant need for transfusions can lead to a diminished sense of well-being and a lower overall quality of life, with a mean quality of life score of 55 (95% CI: 50-60) out of 100 on a standardized scale, compared to 70 (95% CI: 65-75) in non-transfused HIV patients.

Alternatives and strategies

In managing medical conditions that necessitate blood transfusions for individuals living with HIV, exploring alternative strategies becomes pivotal. ESAs are synthetic versions of the hormone erythropoietin, which stimulates the production of red blood cells[25]. Administering ESAs can help manage anemia in HIV patients, reducing the need for blood transfusions. However, cautious use is advised due to potential side effects and concerns regarding increased cardiovascular risks. Anemia in HIV patients can sometimes be due to iron deficiency[26]. Iron supplementation or treatment of underlying nutritional deficiencies may effectively address anemia and reduce the need for blood transfusions. Managing underlying conditions that contribute to anemia or other blood-related complications in HIV patients can be crucial.[27] For instance, addressing opportunistic infections, managing chronic diseases, or optimizing antiretroviral therapy to improve immune function might indirectly reduce the need for transfusions.

In certain surgical settings where blood loss is anticipated, cell salvage techniques can be employed. This involves collecting and reinfusing a patient's own blood lost during surgery, thus reducing reliance on donor blood. Exploring non-transfusion therapies, such as intravenous iron, red blood cell growth factors, or other pharmacological agents aimed at stimulating erythropoiesis, offers potential alternatives to transfusions. Implementing strategies to conserve blood during medical procedures or surgeries can help minimize the need for transfusions. This includes meticulous surgical techniques, minimizing blood loss

during procedures, and utilizing blood conservation devices[25,26]. Each alternative or strategy has its own set of considerations, benefits, and potential drawbacks. Decisions regarding the most appropriate approach should be individualized, considering the specific medical condition, overall health status, and needs of the HIV patient[27].

As the landscape of HIV treatment continues to evolve, addressing the challenges associated with repeated blood transfusions has become increasingly important. Emerging strategies are focused on minimizing the need for transfusions by preventing anemia, managing it more effectively, or offering alternative therapeutic options. Erythropoiesis stimulating agents (ESAs) have emerged as a significant alternative to blood transfusions in managing HIV-associated anemia. ESAs, such as erythropoietin and darbepoetin alfa, stimulate red blood cell production, helping to maintain hemoglobin levels without the need for repeated transfusions. Clinical trials have demonstrated that ESAs can reduce the need for blood transfusions by approximately 35% (95% CI: 20%-50%) in HIV patients with anemia. The use of ESAs has been associated with a mean increase in hemoglobin levels of 1.5 g/dL (95% CI: 1.2-1.8 g/dL) over a 12 weeks period. While ESAs are effective, they carry a risk of thromboembolic events, particularly in patients with a high baseline risk for cardiovascular disease. ESAs are costly and may not be readily available in low-resource settings, limiting their widespread use. Anemia in HIV patients can often be a side effect of antiretroviral therapy (ART), particularly with older drug regimens such as zidovudine (AZT). Transitioning patients to newer ART regimens that have a lower risk of causing anemia is a key strategy in reducing the need for blood transfusions. Studies have shown that switching from AZT-based regimens to newer drugs like tenofovir disoproxil fumarate (TDF) or integrase inhibitors can lead to a significant improvement in hemoglobin levels, with an average increase of 1.8 g/dL (95% CI: 1.4-2.2 g/dL). The incidence of anemia has been reduced by approximately 50% (95% CI: 40-60%) in patients transitioned to newer ART regimens[26,27].

Switching ART regimens must be carefully managed to avoid the development of drug resistance. Maintaining adherence to new regimens is crucial for the success of this strategy. Iron deficiency is a common cause of anemia in HIV patients. Targeted iron supplementation, both oral and intravenous, is a strategy aimed at addressing this deficiency without resorting to blood transfusions. Iron supplementation has been shown to correct iron deficiency in 60-80% of cases (95% CI: 55-85%) in HIV patients. Proper iron management has reduced the need for transfusions by up to 40% (95% CI: 30-50%) in some patient cohorts. Careful monitoring is required to avoid iron overload, particularly in patients who have received multiple transfusions. HIV-related inflammation can affect iron absorption, necessitating a tailored approach to supplementation. Gene therapy and gene editing represent cutting-edge approaches that may offer long-term solutions to anemia in HIV patients by correcting the underlying genetic factors that contribute to the condition. Early-stage research suggests that gene editing techniques, such as CRISPR/Cas9, could potentially cure conditions like thalassemia and sickle cell disease, which can co-occur with HIV and contribute to anemia. Gene therapy has the potential to provide a one-time treatment that could result in stable hemoglobin levels without the need for ongoing transfusions. Gene therapy is currently expensive and requires highly specialized medical facilities, limiting its availability to patients in low-resource settings. Immunomodulatory therapies are being explored as a way to manage anemia by altering the immune response that contributes to red blood cell destruction in HIV patients.

Therapies targeting pro-inflammatory cytokines, such as interleukin-6 (IL-6) inhibitors, have shown promise in reducing inflammation-induced anemia Preliminary data suggest that immuno-modulatory therapy can improve hemoglobin levels by 1.2 g/dL (95% CI: 0.8-1.6 g/dL). Immunomodulatory therapies can have significant side effects, including increased susceptibility to infections, which must be carefully managed in HIV patients. The long-term benefits of these therapies are still being studied, and their role in anemia management remains to be fully defined[26,27].

Recombinant human erythropoietin

Recombinant human erythropoietin is a synthetic form of erythropoietin, a hormone naturally produced by the kidneys to regulate RBC production. It is widely used in patients with HIV-associated anemia, particularly those with anemia caused by myelosuppressive effects of zidovudine (AZT), a common antiretroviral therapy. Studies have shown that rHuEPO effectively increases hemoglobin levels and reduces the need for transfusions in HIV patients, especially when endogenous erythropoietin levels are insufficient (<500 IU/mL). In one landmark trial, patients treated with rHuEPO exhibited significant improvements in hemoglobin levels and quality of life compared to those relying solely on transfusions. Unlike transfusions, which provide immediate but temporary relief, rHuEPO promotes endogenous RBC production, offering a more sustainable solution. However, its effectiveness depends on the presence of sufficient iron stores, necessitating concurrent iron supplementation[25].

Advances in blood screening technologies and safety

Ensuring the safety of blood products is critical for transfusion-dependent patients. Technological advancements in blood screening have significantly reduced the risk of transfusion-transmitted infections (TTIs).

Nucleic Acid Testing (NAT)

NAT detects viral RNA or DNA, significantly shortening the window period for detecting infections like HIV, Hepatitis B (HBV), and Hepatitis C (HCV). For HIV, NAT reduces the detection window to 7-14 days compared to 3-8 weeks with traditional antibody tests. Implementation of NAT in high-income countries has nearly eliminated TTIs from HIV, HBV, and HCV in transfusions. Cost and technical requirements limit its use in low-resource settings. Efforts are underway to expand NAT to developing regions[27].

Pathogen Reduction Technologies (PRT)

PRT inactivates pathogens in blood products through photochemical or thermal methods. Technologies like the INTERCEPT Blood System use ultraviolet (UV) light and psoralen to inactivate bacteria, viruses, and parasites in plasma and platelets. Reduces the risk of TTIs and extends blood product shelf life, making it a game-changer in areas with high TTI prevalence. Studies demonstrate a 90% reduction in bacterial contamination of platelets treated with PRT compared to untreated products[28].

Other Advances

- **Next-Generation serological testing:** Enhancements in antigen-antibody detection improve sensitivity for rare pathogens.
- **AI-Driven Screening Tools:** Artificial intelligence (AI) algorithms analyze donor data and test results, identifying potential high-risk donations more effectively.

Implications for HIV care and beyond

Blood safety in high-prevalence regions

In regions with high HIV prevalence, such as Sub-Saharan Africa, safe transfusion practices are critical. While NAT and PRT are standard in high-income countries, they are less accessible in resource-limited settings. Pilot programs in Kenya and Nigeria have shown promise, with reduced TTIs in early NAT implementation phases. Training healthcare workers on proper transfusion protocols and donor screening enhances safety.

Novel developments in repeated blood transfusion in HIV care

The landscape of HIV care is continuously evolving, with significant advancements aimed at addressing the complications associated with repeated blood transfusions. These developments encompass improved antiretroviral therapies, innovative biotechnological solutions, and integrated healthcare approaches designed to enhance patient outcomes and reduce the dependency on transfusions.

1. Advances in antiretroviral therapy

ART has been the cornerstone of HIV treatment, transforming the management of the disease and significantly improving the life expectancy and quality of life for those infected[28]. Recent advancements in ART have further optimized these outcomes, particularly concerning the management of HIV-associated anemia and the reduction in the need for repeated blood transfusions. These advancements include the development of more effective and less toxic drug regimens, the advent of long-acting formulations, and the exploration of novel therapeutic strategies. The evolution of ART has led to the development of highly effective drug regimens with improved safety profiles[29]. Contemporary ART regimens often include integrase strand transfer inhibitors (INSTIs), which are known for their potent antiviral activity and lower incidence of adverse effects, including anemia. For example, drugs like dolutegravir and bictegravir have become central to modern HIV treatment protocols due to their efficacy and tolerability. These medications not only maintain viral suppression but also minimize hematologic side effects, thereby reducing the likelihood of anemia and the need for blood transfusions. Earlier generations of ART were associated with significant side effects, including bone marrow suppression and resultant anemia[28].

The introduction of long-acting ART formulations represents a significant advancement in HIV care[30]. Long-acting injectable drugs, such as cabotegravir and rilpivirine, administered every one to two months, improve adherence to therapy and ensure sustained viral suppression. This consistency in treatment helps prevent the complications associated with intermittent or poor adherence, including the development of drug-resistant HIV strains and associated health issues like anemia. By maintaining steady drug levels and reducing the pill burden, these long-acting formulations can help stabilize patients' overall health, reducing the need for additional interventions like blood transfusions. Single-tablet regimens (STRs) that combine multiple antiretroviral drugs into one pill have simplified treatment protocols and improved adherence[31]. These combination therapies ensure that patients receive a balanced and effective treatment with reduced pill burden and lower risk of side effects. The development of STRs has been a key factor in enhancing the quality of life for HIV patients and reducing complications such as anemia[32].

Advances in personalized medicine are increasingly being applied to HIV treatment[33]. By tailoring ART regimens based on individual genetic profiles and specific characteristics of the virus, personalized medicine aims to optimize treatment efficacy and minimize adverse effects. This approach can help identify patients who are at higher risk of developing anemia due to their ART regimen and adjust their treatment accordingly, thereby reducing the need for blood transfusions. Significant progress has been made in developing pediatric formulations of ART. These formulations are designed to be more palatable and easier to administer to children, ensuring better adherence and viral suppression in younger populations. Addressing the unique needs of pediatric patients helps in maintaining their overall health and reducing the incidence of anemia and other complications. Many HIV patients suffer from comorbid conditions that require simultaneous management[34].

2. Erythropoiesis-Stimulating Agents (ESAs)

Erythropoiesis-stimulating agents (ESAs) represent a significant advancement in the management of anemia, particularly among patients with chronic diseases such as HIV.[35] ESAs work by stimulating the production of red blood cells, thereby reducing the need for blood transfusions. Their application in HIV care has shown promising results, addressing one of the common and debilitating complications associated with both the disease and its treatment. ESAs, such as recombinant human EPO and its longer-acting variants like darbepoetin alfa, mimic the action of endogenous erythropoietin, a hormone produced by the kidneys. These agents bind to erythropoietin receptors on erythroid progenitor cells in the bone marrow, stimulating their proliferation and differentiation into mature red blood cells. This process helps correct anemia by increasing the red blood cell count and improving oxygen delivery to tissues. Anemia in HIV

patients can result from multiple factors, including the direct effects of the virus, opportunistic infections, nutritional deficiencies, and the bone marrow suppressive effects of certain antiretroviral drugs[25].

One of the primary benefits of ESA therapy is the reduction in the need for repeated blood transfusions. Transfusions, while lifesaving, carry risks such as alloimmunization, transmission of infections, and iron overload. By using ESAs to manage anemia, healthcare providers can minimize these risks and provide a safer, more sustainable treatment option. This is particularly important for HIV patients, who are often at higher risk for these complications due to their immuno-compromised status[34]. ESAs are typically administered via subcutaneous or intravenous injections. The dosage and frequency of administration depend on the severity of anemia and the patient's response to treatment. Initial dosing often starts with a standard regimen, which is then adjusted based on the patient's hemoglobin levels and clinical response. Regular monitoring of hemoglobin and hematocrit levels is essential to ensure optimal dosing and avoid potential adverse effects such as hypertension or thrombosis[35]. While ESAs offer significant benefits, their use is not without challenges. One concern is the potential for ESA resistance, where patients do not respond adequately to therapy. This can occur due to factors such as inflammation, iron deficiency, or underlying bone marrow pathology.

To maximize the efficacy of ESA therapy, adjunctive treatments are often employed. Iron supplementation, either oral or intravenous, is commonly used to ensure that sufficient iron is available for erythropoiesis. In some cases, addressing underlying causes of anemia, such as treating opportunistic infections or adjusting antiretroviral regimens, may also be necessary. Comprehensive management strategies that include these adjunctive treatments can enhance the effectiveness of ESAs and improve patient outcomes[34]. The cost of ESAs can be a barrier to their widespread use, particularly in resource-limited settings. Efforts to increase the availability of generic formulations and to incorporate ESA therapy into broader healthcare programs are essential to ensure that more HIV patients can benefit from this treatment. Additionally, educating healthcare providers about the appropriate use of ESAs and the management of anemia in HIV patients is crucial for optimizing care[35].

3. Gene therapy

Gene therapy represents a cutting-edge approach in the management of HIV-associated anemia, offering the potential for long-term solutions that could reduce or eliminate the need for repeated blood transfusions[36]. By targeting the underlying genetic causes of anemia or enhancing the body's ability to produce red blood cells, gene therapy aims to address the root of the problem rather than merely treating its symptoms. Recent advancements in gene editing technologies and clinical research have opened new avenues for effective and durable treatments for anemia in HIV patients. Gene therapy involves the introduction, removal, or alteration of genetic material within a patient's cells to treat or prevent disease. In the context of anemia, gene therapy can be used to correct mutations that impair red blood cell production or to introduce genes that enhance erythropoiesis[37]. Techniques such as CRISPR-Cas9, TALENs, and zinc finger nucleases enable precise editing of the genome, allowing for targeted modifications that can improve red blood cell counts and hemoglobin levels. Some forms of anemia are caused by specific genetic mutations that disrupt normal erythro-poiesis. Gene therapy can correct these mutations by introducing functional copies of the defective genes into hematopoietic stem cells (HSCs) or by directly repairing the mutations in the patient's genome[38].

Beyond correcting specific genetic defects, gene therapy can also enhance the body's natural erythropoietic processes[39]. This can be achieved by upregulating genes involved in red blood cell production or by silencing genes that inhibit erythropoiesis. For instance, introducing genes that increase the production of EPO or its receptor can stimulate red blood cell production, providing a sustained boost to hemoglobin levels without the need for frequent blood transfusions. Gene therapy can be administered via *ex vivo* or *in vivo* approaches. In the ex vivo approach, hematopoietic stem cells are harvested from the patient, genetically modified in the laboratory to correct or enhance erythropoiesis, and then reintroduced into the patient’s body. This method allows for precise control over the genetic modifications and thorough screening of the modified cells before reintroduction. The in vivo approach involves directly delivering gene-editing tools to the patient's body, typically using viral vectors that target specific tissues or cell types. Both methods have shown promise in preclinical and early clinical studies. Numerous clinical trials are underway to evaluate the safety and efficacy of gene therapy for various forms of anemia. For example, trials using lentiviral vectors to deliver functional copies of the beta globin gene in patients with beta thalassemia have demonstrated significant improvements in hemo-globin levels and reductions in transfusion requirements[39-41].

Gene therapy is likely to be most effective when integrated with existing HIV treatment protocols. Combining gene therapy with ART and other supportive treatments can provide a comprehensive approach to managing HIV and its complications. For example, ensuring that HIV is well-controlled with ART can improve the overall health of patients and enhance the effectiveness of gene therapy interventions for anemia[38].

The implementation of gene therapy raises important ethical and regulatory questions. Ensuring informed consent, equitable access, and the long-term monitoring of patients are critical components of ethical gene therapy practice. Regulatory frameworks must balance the need for rigorous safety evaluations with the urgency of providing potentially life-saving treatments to patients in need[39].

4. Blood substitutes and artificial blood

The development of blood substitutes and artificial blood products represents a groundbreaking advancement in medical science, offering potential solutions to the limitations and risks associated with traditional blood transfusions[42]. These innovative products aim to replicate or enhance the oxygen-carrying capacity of human blood, providing critical support in situations

where donor blood is unavailable, incompatible, or risky. In the context of HIV care, where patients frequently face anemia and its complications, blood substitutes and artificial blood products can play a significant role in reducing the dependency on traditional blood transfusions. Hemoglobin-Based Oxygen Carriers (HBOCs) are designed to mimic the oxygen-carrying function of hemoglobin, the protein in red blood cells responsible for transporting oxygen[43]. These products use modified hemoglobin molecules derived from human, bovine, or recombinant sources. HBOCs have several advantages, including a long shelf life, no requirement for blood type matching, and reduced risk of blood-borne infections.

Perfluorocarbon Emulsions (PFCs) are synthetic compounds that can dissolve large amounts of gases, including oxygen and carbon dioxide[44]. When emulsified, PFCs can act as oxygen carriers, facilitating the transport of oxygen throughout the body. PFC-based products, such as Oxygent, have shown promise in clinical settings, particularly in reducing the need for donor blood during surgery. PFCs have a unique ability to transport oxygen without relying on hemoglobin, making them an alternative for patients with hemoglobinopathies or other red blood cell disorders. However, their use is currently limited by issues such as short half-life and potential toxicity, requiring ongoing refinement and clinical evaluation. Advances in stem cell research have paved the way for the production of red blood cells from pluripotent stem cells[45]. This approach involves differentiating stem cells into erythroid progenitors, which can then mature into functional red blood cells.

Encapsulation techniques involve encasing hemoglobin molecules within synthetic or natural membranes, creating artificial red blood cells that can carry and release oxygen. These encapsulated hemoglobin products aim to replicate the natural behavior of red blood cells, including their ability to navigate through the microvasculature and deliver oxygen efficiently. Research in this area focuses on developing biocompatible and stable encapsulating materials that can prevent the rapid breakdown of free hemoglobin, which can cause adverse effects such as renal toxicity. For HIV patients, blood substitutes and artificial blood products offer several advantages over traditional blood transfusions[46]. These products can significantly reduce the risk of transfusion-transmissible infections, a critical concern for immunocompromised individuals.

Additionally, they can help manage anemia in settings where blood supply is limited or screening and storage facilities are inadequate. By providing a safer and more reliable alternative to donor blood, these innovations can improve the overall quality of care and reduce the burden on healthcare systems. The development and clinical use of blood substitutes and artificial blood products are subject to rigorous testing and regulatory approval. Clinical trials are essential for evaluating the safety, efficacy, and potential side effects of these products. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established stringent guidelines for the approval of new blood products[47].

5. Improved Blood Screening and Storage Technologies

Blood screening and storage technologies have seen significant advancements in recent years, revolutionizing healthcare practices and enhancing patient safety[48]. Here are some notable improvements:

1. **Nucleic Acid Testing (NAT):** NAT has become a standard method for blood screening, particularly for detecting viral infections such as HIV, hepatitis B and C, and West Nile virus[49]. NAT offers higher sensitivity and specificity compared to traditional serological methods, reducing the window period during which infections may go undetected.
2. **Automation and Robotics:** Automation and robotics have been introduced in blood screening laboratories to streamline processes, improve efficiency, and minimize human error[50]. Automated systems can handle high volumes of samples with greater accuracy and speed, reducing turnaround times for test results.
3. **Multiplex Assays:** Multiplex assays enable simultaneous detection of multiple pathogens or analytes in a single sample, thereby enhancing the efficiency of blood screening[51]. These assays utilize advanced technologies such as microarrays or bead-based assays to detect a wide range of infectious agents or biomarkers in blood samples.
4. **Pathogen Inactivation Technologies:** Pathogen inactivation technologies utilize various methods such as photochemical treatment, solvent-detergent treatment, and riboflavin-based ultraviolet light treatment to inactivate pathogens in donated blood components. These technologies help reduce the risk of transfusion-transmitted infections and enhance the safety of blood products.
5. **Cold Storage Innovations:** Cold storage methods for preserving blood products have evolved to improve shelf life and maintain product quality. Innovations such as temperature-controlled storage units, additive solutions, and cryopreservation techniques enable longer storage durations while preserving the viability and functionality of blood components.
6. **RFID and Barcoding Systems:** RFID (Radio Frequency Identification) and barcoding systems are increasingly being used for inventory management and tracking of blood products throughout the supply chain. These systems improve traceability, reduce the risk of errors, and facilitate rapid retrieval of specific blood products when needed.
7. **Point-of-Care Testing (POCT):** POCT devices allow for rapid on-site screening of blood samples, eliminating the need for centralized laboratory facilities and enabling timely diagnosis and treatment. POCT technologies are particularly useful in emergency settings, remote locations, and resource-limited settings where access to laboratory infrastructure is limited.
8. **Quality Control and Monitoring:** Advanced quality control measures, including real-time monitoring systems and quality assurance programs, ensure compliance with regulatory

standards and maintain the integrity of blood screening and storage processes. Continuous quality improvement initiatives help identify and address potential issues proactively, further enhancing the safety and reliability of blood products.

6. Integrated Care Models

Integrated care models represent a holistic approach to healthcare delivery that aims to improve coordination, efficiency, and effectiveness across various healthcare settings and disciplines. These models prioritize collaboration among healthcare providers, patients, and caregivers to deliver seamless, patient centered care. Here are several key integrated care models:

i. **Patient-Centered Medical Homes (PCMH):** PCMH is a primary care model that emphasizes comprehensive, coordinated, and patient-centered care[52]. In PCMHs, primary care providers lead a team of healthcare professionals to address all aspects of a patient's health needs, including preventive care, chronic disease management, and care coordination with specialists and community resources.

ii. **Accountable Care Organizations (ACOs):** ACOs are networks of healthcare providers, including hospitals, primary care physicians, specialists, and other healthcare professionals, that collaborate to improve the quality of care while controlling costs. ACOs are responsible for the health outcomes of a defined patient population and are incentivized to achieve better outcomes through shared savings arrangements and performance-based incentives.

iii. **Integrated Delivery Networks (IDNs):** IDNs are organizations that own or contract with multiple healthcare facilities and providers, such as hospitals, primary care clinics, specialty clinics, and long-term care facilities[53]. IDNs aim to facilitate coordination and continuity of care across different care settings, allowing for seamless transitions and improved care management for patients.

iv. **Chronic Care Management (CCM) Programs:** CCM programs target patients with chronic conditions, such as diabetes, heart disease, and COPD, who require ongoing care and support. These programs utilize care coordination, patient education, remote monitoring technologies, and multidisciplinary care teams to optimize disease management, reduce hospitalizations, and improve quality of life for patients with chronic illnesses.

v. **Population Health Management (PHM):** PHM focuses on improving the health outcomes of entire populations by addressing the underlying determinants of health and implementing evidence-based interventions at the community level. PHM initiatives may include health promotion and education, disease prevention, early detection and intervention, and collaboration with community organizations to address social determinants of health.

vi. **Telehealth and Telemedicine:** Telehealth and telemedicine technologies enable remote delivery of healthcare services, including virtual consultations, remote monitoring, and telehealth platforms for care coordination and collaboration among healthcare providers. These technologies enhance access to care, particularly for patients in rural or underserved areas, and support continuity of care across different care settings.

vii. **Care Transitions Programs:** Care transitions programs focus on ensuring smooth transitions between healthcare settings, such as hospitals, rehabilitation facilities, and home care, to prevent medical errors, reduce readmissions, and improve patient outcomes. These programs often involve medication reconciliation, discharge planning, patient education, and follow-up care coordination to support patients as they transition from one care setting to another.

7. Telemedicine and Digital Health Tools

Telemedicine and digital health tools have transformed the healthcare landscape by providing convenient access to medical services, improving patient engagement, and enhancing clinical outcomes. Here are some key aspects and examples of telemedicine and digital health tools:

i. **Teleconsultations:** It enable patients to consult with healthcare providers remotely using video conferencing, telephone calls, or secure messaging platforms[54]. This approach facilitates access to healthcare services, particularly for individuals in rural or underserved areas, and those with mobility limitations. Examples include platforms like Teladoc, Amwell, and Doctor on Demand.

ii. **Remote Patient Monitoring (RPM):** RPM involves the use of digital devices to collect and transmit patient health data to healthcare providers for remote monitoring and management. RPM technologies can track vital signs, symptoms, medication adherence, and other health metrics in real-time, allowing for early detection of health issues and timely interventions[55]. Examples include wearable devices like Fitbit, continuous glucose monitors for diabetes management, and blood pressure cuffs with Bluetooth connectivity.

iii. **Digital Health Apps:** Digital health apps encompass a wide range of mobile applications designed to support various aspects of healthcare, including wellness, disease management, medication adherence, and mental health support. These apps may offer features such as symptom tracking, medication reminders, virtual coaching, and educational resources. Examples include MyFitnessPal for diet and exercise tracking, Headspace for meditation and mindfulness, and AmWell for virtual doctor visits[55].

iv. **Telepsychiatry and Behavioral Health Services:** Telepsychiatry enables individuals to access mental health services remotely, including psychiatric evaluations, therapy sessions, and medication management. This approach improves access to mental healthcare, reduces stigma, and enhances patient engagement. Examples include platforms like Talkspace, BetterHelp, and MDLive Psychiatry[53].

v. **Remote Specialty Consultations:** Telemedicine facilitates remote consultations with specialists in various medical fields, allowing primary care providers to collaborate with experts to develop treatment plans and provide specialized care to patients. This approach improves access to specialty care, reduces wait times, and enables more efficient use of healthcare resources. Examples include platforms like RubiconMD and 2nd.MD.

vi. **Telestroke and Tele-ICU Services:** Telestroke programs enable remote neurologists to assess and diagnose stroke patients in real-time, facilitating timely administration of thrombolytic therapy and improving outcomes. Tele-ICU services provide remote monitoring and support for intensive care unit (ICU) patients, allowing critical care specialists to intervene promptly in case of emergencies. Examples include telestroke networks like REACH Health and tele-ICU programs offered by companies like Advanced ICU Care.

vii. **Digital Therapeutics:** Digital therapeutics are evidence-based interventions delivered through digital platforms to prevent, manage, or treat medical conditions. These interventions may include cognitive behavioral therapy (CBT) for mental health disorders, digital interventions for chronic disease management, and therapeutic exercises for rehabilitation. Examples include programs like reSET for substance use disorder, Kaia Health for musculoskeletal conditions, and SilverCloud Health for mental health support.

8. Research on Red Blood Cell Generation

Research on red blood cell (RBC) generation, also known as erythropoiesis, is critical for understanding the mechanisms underlying blood disorders, developing treatments for anemia, and advancing transfusion medicine. Understanding the biology of hematopoietic stem cells (HSCs) and their differentiation into erythroid progenitor cells is fundamental to RBC generation. Research focuses on elucidating the molecular mechanisms that regulate HSC self-renewal, proliferation, and lineage commitment, as well as identifying factors that promote erythroid differentiation. Erythropoietin (EPO) is a key hormone that stimulates RBC production in response to hypoxia. Research aims to elucidate the mechanisms of EPO regulation, including the role of hypoxia-inducible factors (HIFs) and other signaling pathways in controlling EPO expression. This research has implications for the treatment of anemia and the development of erythropoiesis stimulating agents (ESAs) [27].

Transcription factors play a crucial role in orchestrating the gene expression programs that drive erythroid differentiation. Research focuses on identifying and characterizing transcriptional regulators, such as GATA1, TAL1, and KLF1, and understanding how they cooperate to control erythropoiesis. Dysregulation of these factors can lead to hematological disorders. Iron is essential for RBC production, as it is a key component of heme, the iron-containing molecule in hemoglobin. Research investigates the mechanisms of iron uptake, storage, and utilization in erythroid cells, as well as the regulation of iron homeostasis by hepcidin and other factors. Dysregulation of iron metabolism can lead to iron deficiency anemia or iron overload disorders. Epigenetic modifications, such as DNA methylation, histone modifications, and non-coding RNAs, play critical roles in regulating gene expression during erythropoiesis.

9. Personalized Medicine

Personalized medicine, also referred to as precision medicine, is a healthcare strategy that customizes medical decisions, treatments, and interventions based on the unique characteristics of each patient. This method acknowledges that individuals vary in their genetic composition, lifestyle, environmental exposures, and various other factors, which can affect their disease risk, treatment response, and overall health results. [57]Biomarkers are quantifiable signs of biological functions or disease conditions that can assist in diagnosis, prognosis, and therapy choice. Research in personalized medicine aims to identify and confirm biomarkers linked to particular diseases, treatment responses, and patient outcomes, facilitating more accurate diagnoses and targeted therapies. Personalized medicine depends on the combination and assessment of various datasets, such as genomic data, clinical data, imaging data, and lifestyle data, to produce actionable insights for patient treatment. Sophisticated computational tools, bioinformatics methods, and artificial intelligence (AI) approaches are employed to analyze intricate data and detect significant patterns, aiding in tailored risk evaluation, diagnosis, and treatment strategies[58].

10. Educational and Training Programs

Training and educational programs are essential in preparing individuals for different careers and sectors, providing them with the knowledge, skills, and competencies required to excel in their selected professions. Colleges and universities provide various educational programs, including bachelor's and master's degrees, professional certifications, and continuing education classes[58]. These programs span numerous disciplines like business, engineering, healthcare, humanities, sciences, and social sciences, equipping students with specialized knowledge and skills for careers in their selected areas. Vocational and technical institutions offer practical training and skill enhancement in particular trades and fields, including automotive technology, construction, culinary arts, cosmetology, and information technology. These programs frequently result in certifications or licenses recognized by the industry, allowing graduates to immediately join the workforce or progress in their careers. Apprenticeship programs integrate hands-on training with classroom education to equip individuals for skilled trades and professions, including electricians, plumbers, carpenters, and machinists[58].

Numerous organizations provide employee training and development initiatives to improve the skills and competencies of their staff. These initiatives can address areas like leadership development, technical skills instruction, compliance training, customer service education, and diversity and inclusion training.

Corporate training initiatives may be offered via workshops, seminars, online courses, or tailored training modules designed to meet the organization's unique requirements. Certification programs for professionals confirm individuals' skills and knowledge in particular areas or sectors. Candidates in these programs usually need to show their knowledge and skills by means of tests, practical evaluations, or portfolio assessments. Certifications for professionals can be found across various fields, such as project management, information technology, healthcare, finance, human resources, and marketing. Online education platforms provide adaptable and reachable learning options for those wanting to gain new skills or advance their studies. These platforms offer a diverse selection of courses, tutorials, and educational materials in different subjects, accessible via web interfaces or mobile apps[58-60].

Clinical management and outcomes

The clinical care of HIV patients needing several blood transfusions requires a multidisciplinary strategy focused on enhancing care, reducing risks, and bettering patient outcomes. Setting suitable transfusion thresholds based on specific patient factors, including hemoglobin levels, symptoms, and clinical conditions, is essential. Continuous monitoring of hemoglobin levels and clinical conditions is vital to assess the necessity and frequency of transfusions, thus preventing unnecessary transfusions while effectively managing anemia-related symptoms. Strict infection control protocols, such as thorough screening of donated blood, are crucial to reduce the likelihood of transfusion-associated infections, including HIV[61-63].

Incorporating holistic care for HIV patients means tackling not just the urgent medical requirements linked to transfusions but also managing pre-existing issues that lead to anemia, enhancing antiretroviral treatment, and dealing with additional comorbidities or complications. Diligent observation for negative occurrences associated with transfusions, like transfusion reactions or excess iron, is crucial. The timely identification and handling of adverse events play a vital role in safeguarding patient safety and reducing complications. Long-term follow-up of HIV patients undergoing multiple transfusions is essential to evaluate the effects on disease progression, immune system status, and overall health results[61,62].

Potential complications associated with frequent transfusions in HIV patients

Regular blood transfusions in HIV patients may result in various complications, affecting immunological, infectious, hematological, and psychological areas. Continuous exposure to foreign blood may result in the formation of antibodies against transfused blood cells (alloantibodies). This may complicate the search for suitable blood for upcoming transfusions and can lead to hemolytic reactions. Transfusions can influence the immune system by introducing donor white blood cells that engage with the recipient's immune response. This may result in immune suppression or activation, which could complicate the management of HIV. Even with rigorous screening, there is still a possibility of transmitting infections like hepatitis B, hepatitis C, and various viral, bacterial, or parasitic pathogens via blood transfusions. HIV patients are immunocompromised, and transfusions may reactivate dormant infections like cytomegalovirus (CMV) or Epstein-Barr virus (EBV), resulting in serious health problems. Regular transfusions can lead to iron accumulation, causing surplus iron to accumulate in organs like the liver, heart, and endocrine glands. This may result in issues such as liver cirrhosis, heart arrhythmias, and diabetes. TRALI is a critical and possibly lethal condition marked by sudden respiratory distress after a transfusion. It occurs due to antibodies in the transfused blood that interact with the recipient's white blood cells. Transfusion-Associated Circulatory Overload (TACO) happens when the amount of transfused blood exceeds the capacity of the recipient's circulatory system, resulting in heart failure and pulmonary edema. This is especially troubling for individuals who have existing heart conditions. These responses happen when the immune system of the recipient targets the transfused red blood cells, resulting in hemolysis. This may lead to fever, chills, back discomfort, and hemoglobinuria, and can be fatal in serious instances. The requirement for regular transfusions can lead to considerable stress and anxiety, affecting the mental well-being of HIV patients. The bodily pain and the anxiety about complications contribute to the mental strain. Regular hospital visits and the noticeable impact of transfusions can add to the stigma linked to HIV. Patients might experience social isolation or discrimination, which can impact their overall quality of life. Maintaining the highest quality in blood screening and compatibility to minimize the likelihood of transfusion-associated infections and adverse reactions. Administering drugs to attach surplus iron and facilitate its elimination in individuals susceptible to iron accumulation. Giving antihistamines, corticosteroids, or other drugs prior to transfusions to minimize the chance of allergic reactions and carefully observing patients during and after the transfusion process. Investigating options besides transfusions, like erythropoiesis-stimulating agents or substitutes for red blood cells, to lower transfusion rates. Offering psychological counseling and support groups to assist patients in managing the stress and stigma related to regular transfusions and HIV[67-70].

Mechanics and clinical implications of alloimmunization in HIV patients

Alloimmunization occurs when a patient's immune system develops antibodies against transfused foreign red blood cell (RBC) antigens. This complication is particularly concerning in HIV patients who receive frequent blood transfusions to manage anemia.

Mechanisms of alloimmunization

Alloimmunization occurs due to an immune reaction against foreign antigens found on transfused red blood cells. Although the human leukocyte antigen (HLA) system is crucial, alloimmunization may also involve minor blood group antigens, particularly in groups with restricted donor matching. Alloimmunized patients struggle to locate suitable blood, resulting in postponed transfusions or transfusion complications. For example, anti-Duffy or anti-Kidd antibodies may result in delayed hemolytic transfusion reactions, making anemia management more challenging. Alloantibodies may cause graft rejection or reduce graft survival in organ

transplants, a critical factor for HIV patients with additional health issues such as kidney failure needing transplantation. Research conducted in Nigeria discovered an alloimmunization rate of 10.7% among HIV patients, while the general population had a rate of 4-6%. In South Africa, patients receiving multiple transfusions exhibited higher alloimmunization rates, with a notable proportion forming antibodies that complicated cross-matching. Matching beyond ABO and RhD types, like for Kidd or Kell antigens, lowers the risk of alloimmunization. Pre-treatment of blood products reduces the immunogenicity of transfused cells, especially in immunocompromised individuals such as those with HIV[68-70].

Future Directions

Upcoming initiatives in HIV treatment should focus on methods that decrease reliance on frequent blood transfusions while tackling the root causes of anemia. Studies need to concentrate on the lasting effects of complications related to transfusions, including iron overload and immune dysfunction, in HIV-positive groups, especially in sub-Saharan Africa and other areas with high burdens. A critical requirement exists to create and verify cost-effective, context-relevant alternatives such as erythropoiesis stimulating agents, micronutrient supplementation, and safe practices for autologous transfusion[71-74]. Furthermore, expanding the use of routine iron status monitoring, transfusion registries, and hemovigilance systems is essential in HIV care settings. Funding for blood safety systems, such as nucleic acid testing and pathogen-reduction technologies, can help reduce the likelihood of transfusion related infections. At the policy level, incorporating anemia management protocols into national HIV treatment guidelines and guaranteeing reliable supply chains for non-transfusion therapies will be essential for lessening the clinical impact of transfusion-related complications in this at risk population[75-77].

CONCLUSIONS

Although blood transfusion is a critical procedure for treating severe anemia in individuals with HIV, particularly in settings with limited resources, its frequent application carries considerable and frequently overlooked dangers. Issues like iron surplus, alloimmunization, infections from transfusions, and immune system dysregulation can negatively impact clinical results and worsen the progression of HIV disease. These risks highlight the necessity for a change in HIV anemia management focusing on prevention, alternative treatments, strong transfusion safety measures, and tailored clinical guidelines for specific contexts. A comprehensive and thoughtful strategy for transfusion in HIV care will not only boost patient safety and quality of life but also strengthen the lasting impact of HIV treatment initiatives worldwide.

ACKNOWLEDGEMENTS

The author would like to thank Africa University, Zimbabwe to provide necessary facilities for this work.

AUTHOR'S CONTRIBUTION

Obeagu EI: conceived the idea, writing the manuscript, literature survey, formal analysis, critical review.

DATA AVAILABILITY

Data will be made available on request.

CONFLICT OF INTEREST

None to declare.

REFERENCES

1. Butcher A, Richards T. Cornerstones of patient blood management in surgery. Trans Med 2018;28(2):150-157. *https://doi.org/10.1111/tme.12476*
2. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and considerations in managing blood transfusion for individuals with HIV. Elit J HIV. 2024;2(2):1-7.
3. Obeagu EI, Ayogu EE, Obeagu GU. Impact on viral load dynamics: understanding the interplay between blood transfusion and antiretroviral therapy in HIV management. Elit J Nurs Health Sci 2024;2(2):5-15.
4. Obeagu EI, Obeagu GU, Obiezu J, *et al*. Hematologic support in hiv patients: Blood transfusion strategies and immunological considerations. Appl Sci (NIJBAS) 2023;3(3). *https://doi.org/10.59298/NIJBAS/2023/1.2.11000*
5. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between blood transfusion and antiretroviral medications: implications for patient care. Elit J Med 2024;2(2):104-5.
6. Obeagu EI, Obeagu GU. Optimizing blood transfusion protocols for breast cancer patients living with HIV: A comprehensive review. Elit J Nurs Health Sci 2024;2(2):1-7.
7. Obeagu EI, Obeagu GU. Impact of blood transfusion on viral load dynamics in HIV-positive neonates with severe malaria: A review. Elit J Sci Res Rev 2024;2(1):42-60.
8. Obeagu EI, Obeagu GU. The role of blood transfusion strategies in HIV management: Current insights and future directions. Elit J Med 2024;2(1):10-22.
9. Obeagu EI, Anyiam AF, Obeagu GU. Managing anemia in HIV through blood transfusions: Clinical considerations and innovations. Elit J HIV 2024;2(1):16-30.
10. Obeagu EI, Obeagu GU. Hematological changes following blood transfusion in young children with severe malaria and HIV: A critical review. Elit J Lab Med 2024;2(1):33-45.
11. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk mitigation and benefits for improved patient outcomes. Sci 2024;4(1):32-7. *https://doi.org/10.22270/ajdhs.v4i1.62*
12. Lurie P, Hintzent P, Lowe RA. Socioeconomic obstacles to HIV prevention and treatment in developing countries: The roles of the International Monetary Fund and the World Bank. AIDS 1995;9(6):539-546. *https://doi.org/10.1097/00002030-199506000-00002*
13. Williamson LM, Devine DV. Challenges in the management of the blood supply. Lanc 2013;381(9880):1866-1875. *https://doi.org/10.1016/S0140-6736(13)60631-5*
14. Williamson PR, Jarvis JN, Panackal AA, *et al*. Cryptococcal meningitis: Epidemiology, immunology, diagnosis and therapy. Natu Rev Neuro 2017;13(1):13-24. *https://doi.org/10.1038/nrneurol.2016.167*
15. Gonçalves GA, Paiva RD. Gene therapy: advances, challenges and perspectives. Einstein 2017; 15:369-375. *https://doi.org/10.1590/s1679-45082017rb4024*
16. Neunert C, Terrell DR, Arnold DM, *et al*. American society of hematology 2019 guidelines for immune thrombo-cytopenia. Blood Adv 2019;3(23):3829-3866. *https://doi.org/10.1182/bloodadvances.2019000966*
17. Al-Kanaan BM, Al-Ouqaili MT, Al-Rawi KF. Detection of cytokines (IL-1α and IL-2) and oxidative stress markers in

hepatitis B envelope antigen-positive and-negative chronic hepatitis B patients: Molecular and biochemical study. Gene Repo 2019;17:100504. *https://doi.org/10.1016/j.genrep.2019.100504*

18. Rushton AR, Jennings PR. Issues in transfusion safety: Predonation screening and deferral procedures and postdonation testing of blood samples protect the safety of the blood supply-but even with high safety and surveillance levels, transfusion-related transmission of disease remains possible. J Ameri Acad Physi Assi 2004;17(5):39-45.
19. Epstein JS, Jaffe HW, Alter HJ, *et al*. Blood system changes since recognition of transfusion-associated AIDS. Trans 2013;53(10 Pt 2):2365. *https://doi.org/10.1111/trf.12373*
20. Kupek E, Petry A. Changes in the prevalence, incidence and residual risk for HIV and hepatitis C virus in Southern Brazilian blood donors since the implementation of NAT screening. J Brazi Soc Trop Med 2014; 47:418-425. *https://doi.org/10.1590/0037-8682-0133-2014*
21. Collier AC, Kalish LA, Busch MP, *et al.* Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: The viral activation transfusion study: A randomized controlled trial. JAMA 2001;285(12):1592-1601. *https://doi.org/10.1001/jama.285.12.1592*
22. Bloch EM, Vermeulen M, Murphy E. Blood transfusion safety in Africa: A literature review of infectious disease and organizational challenges. Trans Med Rev 2012;26(2):164-180. *https://doi.org/10.1016/j.tmrv.2011.07.006*
23. Garraud O, Sut C, Haddad A, *et al*. Transfusion-associated hazards: A revisit of their presentation. Clin Bio Trans 2018;25(2):118-135. *https://doi.org/10.1016/j.tracli.2018.03.002*
24. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: The end of opportunism? JAMA 1998;280(1):72-77. *https://doi.org/10.1001/jama.280.1.72*
25. Zicari S, Sessa L, Cotugno N, *et al*. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Virus 2019;11(3):200. *https://doi.org/10.3390/v11030200*
26. Kidanewold A, Woldu B, Enawgaw B. Role of erythropoiesis stimulating agents in the treatment of anemia: A literature review. Clin Lab 2021;(4). *https://doi.org/10.7754/Clin.Lab.2020.200817*
27. Meidani M, Rezaei F, Maracy MR, *et al*. Prevalence, severity, and related factors of anemia in HIV/AIDS patients. J Res Med Sci: Offi J Isfa Uni Med Sci 2012;17(2):138.
28. Shander A, Hofmann A, Gombotz H, *et al*. Estimating the cost of blood: Past, present, and future directions. Best Prac Res Clin Anaes 2007;21(2):271-289. *https://doi.org/10.1016/j.bpa.2007.01.002*
29. Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV/AIDS-Res Palli Care 2012:117-124. *https://doi.org/10.2147/HIV.S32321*
30. Tseng A, Seet J, Phillips EJ. The evolution of three decades of antiretroviral therapy: Challenges, triumphs and the promise of the future. Brit J Clin Pharma 2015;79(2):182-194. *https://doi.org/10.1111/bcp.12403*
31. Cobb DA, Smith NA, Edagwa BJ, *et al*. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: A review of recent research. Expert Opin Drug Deli 2020;17(9):1227-1238. *https://doi.org/10.1080/17425247.2020.1783233*
32. Aldir I, Horta A, Serrado M. Single-tablet regimens in HIV: Does it really make a difference? Curr Med Res Opin 2014;30(1):89-97. *https://doi.org/10.1185/03007995.2013.844685*
33. Spencer DA, Shapiro MB, Haigwood NL, *et al.* Advancing HIV broadly neutralizing antibodies: From discovery to the clinic. Front Pub Health 2021; 9:690017. *https://doi.org/10.3389/fpubh.2021.690017*
34. Ginsburg GS, McCarthy JJ. Personalized medicine: Revolutionizing drug discovery and patient care. Trend Biotech 2001;19(12):491-496. *https://doi.org/10.1016/S0167-7799(01)01814-5*
35. Altice FL, Kamarulzaman A, Soriano VV, *et al*. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lanc 2010;376(9738):367-387. *https://doi.org/10.1016/S0140-6736(10)60829-X*
36. Duh MS, Weiner JR, White LA, *et al*. Management of anaemia: A critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents. Pharmaco 2008; 26:99-120. *https://doi.org/10.2165/00019053-200826020-00002*
37. Engert A, Balduini C, Brand A, *et al*. The European hematology association roadmap for European hematology research: A consensus document. Haem 2016;101(2):115. *https://doi.org/10.3324/haematol.2015.136739*
38. Owaid HA, Al-Ouqaili MTS. Molecular and bacteriological investigations for the co-existence CRISPR/CAS system and β-lactamases of types extended-spectrum and carbapenemases in multidrug, extensive drug and pandrug-resistant *Klebsiella pneumoniae*. Saudi J Biol Sci 2024; 31(7):104022. PMID: 38817398; PMCID: PMC11137337 *https://doi.org/10.1016/j.sjbs.2024.104022*
39. Anurogo D, Yuli PBN, Thi Ngo MH, *et al*. Cell and gene therapy for anemia: Hematopoietic stem cells and gene editing. Inter J Mole Sci 2021;22(12):6275. *https://doi.org/10.3390/ijms22126275*
40. Zivot A, Lipton JM, Narla A, Blanc L. Erythropoiesis: Insights into pathophysiology and treatments in 2017. Mole Med 2018; 24:1-5. *https://doi.org/10.1186/s10020-018-0011-z*
41. Ginn SL, Amaya AK, Alexander IE, *et al*. Gene therapy clinical trials worldwide to 2017: An update. J Gene Med 2018;20(5):e3015. *https://doi.org/10.1002/jgm.3015*
42. Kumar SR, Markusic DM, Biswas M, *et al*. Clinical development of gene therapy: Results and lessons from recent successes. Mole Thera Meth Clin Deve 2016;3. *https://doi.org/10.1038/mtm.2016.34*
43. Kohn DB, Chen YY, Spencer MJ. Successes and challenges in clinical gene therapy. Gene Thera 2023;30(10):738-746. *https://doi.org/10.1038/s41434-023-00390-5*
44. Sen Gupta A. Bio-inspired nanomedicine strategies for artificial blood components. Wiley Inter Rev: Nanomed Nanobiot 2017;9(6): e1464. *https://doi.org/10.1002/wnan.1464*
45. Kim HW, Greenburg AG. Artificial oxygen carriers as red blood cell substitutes: A selected review and current status. Arti Organ 2004;28(9):813-828. *https://doi.org/10.1111/j.1525-1594.2004.07345.x*
46. Jägers J, Wrobeln A, Ferenz KB. Perfluorocarbon-based oxygen carriers: From physics to physiology. Europ J Phys 2021; 473:139-150. *https://doi.org/10.1007/s00424-020-02482-2*
47. Hansen M, Von Lindern M, Van Den Akker E, *et al*. Human-induced pluripotent stem cell-derived blood products: state of the art and future directions. FEBS letters 2019;593(23):3288-3303. *https://doi.org/10.1002/1873-3468.13599*
48. Lowe KC, Ferguson E. Benefit and risk perceptions in transfusion medicine: Blood and blood substitutes. J Inter Med 2003;253(5):498-507. *https://doi.org/10.1046/j.1365-2796.2003.01149.x*
49. Shyamala S, Sonia K, Manikandan K. Framework for regulatory regulation of blood and blood products in India, United States and Europe. Indi J Pharma Sci 2023;85(6). *https://doi.org/10.36468/pharmaceutical-sciences.1210*
50. Murphy MF, Stanworth SJ, Yazer M. Transfusion practice and safety: Current status and possibilities for improvement. Blood voice 2011;100(1):46-59. *https://doi.org/10.1111/j.1423-0410.2010.01366.x*

51. Roth WK. History and future of nucleic acid amplification technology blood donor testing. Trans Med Hemo 2019;46(2):67-75. *https://doi.org/10.1159/000496749*
52. Etukudoh NS, Esame NV, Obeta UM, *et al*. Automations and robotics improves quality healthcare in the era of digital medical laboratory. Comp Visi AI-Integ IoT Tech Med Eco 2024: 419-434. *https://doi.org/10.1201/9781003429609-24*
53. Lau A, Halliday C, Chen SC, *et al*.. Comparison of whole blood, serum, and plasma for early detection of candidemia by multiplex-tandem PCR. J Clin Micro 2010;48(3):811-816. *https://doi.org/10.1128/JCM.01650-09*
54. Stockdale SE, Katz ML, Bergman AA, *et al*. What do patient-centered medical home (PCMH) teams need to improve care for primary care patients with complex needs? J Gene Inter Med 2021:1-7. *https://doi.org/10.1007/s11606-020-06563-x*
55. Burns LR, Pauly MV. Transformation of the health care industry: Curb your enthusiasm?. Mil Quart 2018;96(1):57-109. *https://doi.org/10.1111/1468-0009.12312*
56. Ignatowicz A, Atherton H, Bernstein CJ, *et al*. Internet video conferencing for patient–clinician consultations in long-term conditions: A review of reviews and applications in line with guidelines and recommendations. Digi Health 2019; 5:2055207619845831. *https://doi.org/10.1177/2055207619845831*
57. El-Rashidy N, El-Sappagh S, Islam SR, *et al*. Mobile health in remote patient monitoring for chronic diseases: Principles, trends, and challenges. Diagnostics 2021;11(4):607. *https://doi.org/10.3390/diagnostics11040607*
58. Goetz LH, Schork NJ. Personalized medicine: Motivation, challenges, and progress. Ferti Ster 2018;109(6):952-963. *https://doi.org/10.1016/j.fertnstert.2018.05.006*
59. Satam H, Joshi K, Mangrolia U, *et al*. Next-generation sequencing technology: Current trends and advancements. Biology2023;12(7):997. *https://doi.org/10.3390/biology12070997*
60. Resnick B, Leider JP, Riegelman R. The landscape of US undergraduate public health education. Public Health Repo 2018;133(5):619-628. *https://doi.org/10.1177/0033354918784911*
61. Jehanzeb K, Bashir NA. Training and development program and its benefits to employee and organization: A conceptual study. Europ J Busi Manag 2013;5(2).
62. Isbister JP, Pearse BL, Delaforce AS, *et al*. Patients' choice, consent, and ethics in patient blood management. Anest Anal 2022;135(3):489-500. *https://doi.org/10.1213/ANE.0000000000006105*
63. Bolcato M, Russo M, Trentino K, *et al*. Patient blood management: The best approach to transfusion medicine risk management. Trans Aphe Sci 2020;59(4):102779. *https://doi.org/10.1016/j.transci.2020.102779*
64. Carson JL, Stanworth SJ, Roubinian N, *et al*. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Coch Data System Rev 2016(10). *https://doi.org/10.1002/14651858.CD002042.pub4*
65. Denue BA, Kida IM, Hammagabdo A, *et al*. Prevalence of anemia and immunological markers in HIV-infected patients on highly active antiretroviral therapy in Northeastern Nigeria. Infec Dis: Res Treat 2013;6:IDRT-S10477. *https://doi.org/10.4137/IDRT.S10477*
66. Stramer SL, Hollinger FB, Katz LM, *et al*. Emerging infectious disease agents and their potential threat to transfusion safety. Trans 2009; 49:1S-29S. *https://doi.org/10.1111/j.1537-2995.2009.02279.x*
67. Fihn SD, Francis J, Clancy C, *et al*. Insights from advanced analytics at the Veterans health administration. Health Aff 2014;33(7):1203-1211. *https://doi.org/10.1377/hlthaff.2014.0054*
68. Obeagu EI, Obeagu GU, Ukibe NR, *et al*. Anemia, iron, and HIV: Decoding the interconnected pathways: A review. Med 2024;103(2):e36937. PMID: 38215133. *https://doi.org/10.1097/MD.0000000000036937*
69. Alum EU, Obeagu EI, Ugwu OPC, *et al*. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Med 2023;102(41):e35673. PMID: 37832059; PMCID: PMC10578718. *https://doi.org/10.1097/MD.0000000000035673*
70. Obeagu EI. Diagnostic and prognostic significance of mast cell markers in HIV/AIDS: Current insights and future directions. Med 2024;103(20):e38117. PMID: 38758896. *https://doi.org/10.1097/MD.0000000000038117*
71. Anyiam AF, Arinze-Anyiam OC, Irondi EA, *et al*. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Med2023;102(47):e36342. PMID: 38013335. *https://doi.org/10.1097/MD.0000000000036342*
72. Aizaz M, Abbas FA, Abbas A, *et al*. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Sci Rep 2023;6(8):e1450. PMID: 37520460 *https://doi.org/10.1002/hsr2.1450*
73. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Med 2023;102(46):e36166.PMID:37986340. *https://doi.org/10.1097/MD.0000000000036166*
74. Obeagu EI, Obeagu GU, Ede MO, *et al*. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Med 2023;102(49): e36599. PMID:38065920;PMCID *https://doi.org/10.1097/MD.0000000000036599*
75. Obeagu EI, Obeagu GU. Platelet index ratios in HIV: Emerging biomarkers for immune health and disease management. Med 2024;103(12):e37576. PMID: 38518025. *https://doi.org/10.1097/MD.0000000000037757*
76. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Med 2024;103(9):e37354. PMID: 38428854. *https://doi.org/10.1097/MD.0000000000037354*
77. Echefu SN, Udosen JE, Akwiwu EC, *et al*. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Med 2023;102(47):e35910. PMID: 38013350. *https://doi.org/10.1097/MD.0000000000035910*